Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has grabbed attention from the analysts, when it saw a value decrease of -23.35% or -0.08 points in the last trading session to close at $0.27. A total of 6.11 Million shares exchanged hands during the intra-day trade compared with its average trading volume of 586.48 Million shares, while its relative volume stands at 11.99. Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has a market cap of $8.18 Million and the number of outstanding shares have been calculated 30.83 Million.
Shares of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) currently have an Average Brokerage Recommendation of 1, number of Recs in ABR is 1 while industry rank of the company by ABR is out of 265. Out of the analyst recommendations 0 rate Immune Pharmaceuticals Inc. (NASDAQ:IMNP) stock a Buy, 1 rate the stock Outperform, 0 rate Hold, 0 rate Underperform and 0 recommend a Sell.
Immune Pharmaceuticals Inc. (NASDAQ:IMNP) as of recent trade, has shown weekly downbeat performance of -23.77% which was maintained at -23.68% in 1-month period. During the past three months the stock slid -49.61%, bringing six months performance to -68.01%. Yearly performance of the stock shows a bearish trend of -89.92% while year-to-date (YTD) performance reflected -53.45% negative outlook.
While taking a glance at financials, we can look at a number of key indicators. Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has trailing twelve month Return on Assets of -107.4%, which is key indicator of how profitable a company is relative to its total assets. The company currently has a Return on Equity of -551.3% and a Return on Investment of 0%. ROI is a performance measure used to evaluate the efficiency of an investment or to compare the efficiency of a number of different investments.
While having a peek at profitability ratios Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has trailing twelve month gross margin at 0%, its trailing twelve month operating margin stands at 0% whereas its trailing twelve month net profit margin spots at 0%.
However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The company’s forward price to earnings ratio for next fiscal year is 0. Immune Pharmaceuticals Inc. (NASDAQ:IMNP)’s price to free cash flow for trailing twelve months is 0. Its beta value stands at 1.69.
The company’s quick ratio for most recent quarter is 0.8 along with current ratio for most recent quarter of 0.8. Total debt to equity ratio of the company for most recent quarter is 0.35 whereas long term debt to equity ratio for most recent quarter is 0.11.